Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 9, 2012, Pages 5221-5226

  Xu, Yu ^a   You, Yongsheng ^a   Du, Wennan ^a   Zhao, Chunhui ^a   Li, Jie ^a   Mao, Jianbo ^a   Chen, Hao ^a   Cheng, Lingyun ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; SILICONE OIL; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE FUNDUS; EYE PHOTOGRAPHY; EYE REFRACTION; NONHUMAN; OPHTHALMOSCOPY; OPTIC NERVE; PRIORITY JOURNAL; RABBIT; VITRECTOMY; ANIMAL; DRUG EFFECT; EYE; INTRAOCULAR DRUG ADMINISTRATION; INTRAOCULAR PRESSURE; METABOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE; INJECTIONS, INTRAOCULAR; INTRAOCULAR PRESSURE; RABBITS; SILICONE OILS; VITRECTOMY;

EID: 84867840400     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9702     Document Type: Article

References (25)

1. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
2. Smit DP, Meyer D. Intravitreal bevacizumab: an analysis of the evidence. Clin Ophthalmol. 2007;1:273-284.
3. Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol. 2011;95:1216-1222.
4. Oshima Y, Shima C, Wakabayashi T, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology. 2009;116:927-938.
5. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhufabv2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005; 46:726-733.
6. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855-859.
7. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-2182.
8. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
9. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009;50: 4807-4813.
10. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology. 2008;115:1750-1755.
11. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009;29:768-774.
12. Falavarjani KG, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye. 2010;24:717-719.
13. Hegazy HM, Kivilcim M, Peyman GA, et al. Evaluation of toxicity of intravitreal ceftazidime, vancomycin, and ganciclovir in a silicone oil-filled eye. Retina. 1999;19:553-557.
14. Cheng L, Hostetler KY, Lee J, et al. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest Ophthalmol Vis Sci. 2004;45:4138-4144.
15. Nan K, Sun S, Li Y, et al. Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Br J Ophthalmol. 2010;94:654-658.
16. Heidenkummer HP, Kampik A, Thierfelder S. Emulsification of silicone oils with specific physicochemical characteristics. Graefes Arch Clin Exp Ophthalmol. 1991;229:88-94.
17. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Amer J Ophthalmol. 2008;146:508-512.
18. Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina. 2011;31:1877-1884.
19. Riviere JE. Comparative Pharmacokinetics. Iowa City, IA: Iowa State Press; 1999:296-307.
20. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695-1705.
21. Matsuyama K, Ogata N, Matsuoka M, Wada M, Nishimura T, Takahashi K. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes. J Ocul Pharmacol Ther. 2011;27:379-383.
22. Perkins SL, Yang CH, Ashton PA, Jaffe GJ. Pharmacokinetics of the ganciclovir implant in the silicone-filled eye. Retina. 2001; 21:10-14.
23. Spitzer MS, Kaczmarek RT, Yoeruek E, et al. The distribution, release kinetics, and biocompatibility of triamcinolone injected and dispersed in silicone oil. Invest Ophthalmol Vis Sci. 2009;50:2337-2343.
24. Falavarjani KG, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye. 2010;24:717-719.
25. Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 2010;51:1606-1608.